ClinicalTrials.gov
ClinicalTrials.gov Menu

C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00688454
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : April 9, 2009
Sponsor:
Information provided by:
AstraZeneca

May 29, 2008
June 3, 2008
April 9, 2009
February 2007
Not Provided
LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin [ Time Frame: 3 visits within 10 weeks ]
Same as current
Complete list of historical versions of study NCT00688454 on ClinicalTrials.gov Archive Site
Tolerability of CRESTOR-therapy [ Time Frame: 3 visits within 10 weeks ]
Same as current
Not Provided
Not Provided
 
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients
Hypercholesteremia
Not Provided
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3392
Same as current
January 2008
Not Provided

Inclusion Criteria:

  • Patients with hypercholesteremia who was never treated with statins before
  • Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00688454
NIS-CCH-CRE-2007/1
No
Not Provided
Not Provided
Dr med Madeleine Billeter, AstraZeneca AG, Switzerland
AstraZeneca
Not Provided
Not Provided
AstraZeneca
April 2009